Business case
A corporate venture capital fund engaged us to perform combined financial and strategic due diligence on a Swiss biotech company. The company had developed an innovative molecule with applications in both the cosmeceutical and nutrition sectors, and it also produced and commercialised consumer health products derived from the molecule.
We provided a fact-based go/no-go investment decision by validating the business plan and market potential of the target, highlighting critical risks and opportunities.
We conducted both financial and strategic due diligence. This included a review of the target’s historical financials, an in-depth market analysis of the longevity market, and a detailed assessment of the business model and go-to-market strategy. We also challenged Management’s business plan and built a revised version.